Recombinant Spike glycoprotein (BTI-Tn-5B1-4)
Taxonomy : Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
SNFG, Text, Oxford
taxonomy (1)
protein (1)
source (1)
structure (0)
composition (66)
disease (1)
reference (2)
site (20)
peptide (108)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) P0DTC2
Protein
- BTI-Tn-5B1-4 (CVCL_C190)
Source
Reported structure
- HexNAc:1 (avg mass : 221.2103 )
- HexNAc:1 dHex:1 (avg mass : 367.3533 )
- HexNAc:1 dHex:2 (avg mass : 513.4963 )
- HexNAc:2 (avg mass : 424.4053 )
- HexNAc:2 dHex:1 (avg mass : 570.5483 )
- HexNAc:2 dHex:2 (avg mass : 716.6913 )
- Hex:1 HexNAc:2 (avg mass : 586.5477 )
- Hex:1 HexNAc:2 dHex:1 (avg mass : 732.6907 )
- Hex:1 HexNAc:2 dHex:2 (avg mass : 878.8337 )
- Hex:2 HexNAc:2 (avg mass : 748.6901 )
- Hex:2 HexNAc:2 dHex:1 (avg mass : 894.8331 )
- Hex:2 HexNAc:2 dHex:2 (avg mass : 1040.9761 )
- Hex:2 HexNAc:3 (avg mass : 951.8851 )
- Hex:2 HexNAc:3 dHex:1 (avg mass : 1098.0281 )
- Hex:2 HexNAc:3 dHex:2 (avg mass : 1244.1711 )
- Hex:2 HexNAc:5 (avg mass : 1358.2751 )
- Hex:3 HexNAc:2 (avg mass : 910.8325 )
- Hex:3 HexNAc:2 dHex:1 (avg mass : 1056.9755 )
- Hex:3 HexNAc:2 dHex:2 (avg mass : 1203.1185 )
- Hex:3 HexNAc:3 (avg mass : 1114.0275 )
- Hex:3 HexNAc:3 dHex:1 (avg mass : 1260.1705 )
- Hex:3 HexNAc:3 dHex:2 (avg mass : 1406.3135 )
- Hex:3 HexNAc:4 (avg mass : 1317.2225 )
- Hex:3 HexNAc:4 dHex:1 (avg mass : 1463.3655 )
- Hex:3 HexNAc:4 dHex:2 (avg mass : 1609.5085 )
- Hex:3 HexNAc:8 (avg mass : 2130.0025 )
- Hex:4 HexNAc:2 (avg mass : 1072.9749 )
- Hex:4 HexNAc:2 dHex:1 (avg mass : 1219.1179 )
- Hex:4 HexNAc:2 dHex:2 (avg mass : 1365.2609 )
- Hex:4 HexNAc:3 (avg mass : 1276.1699 )
- Hex:4 HexNAc:3 dHex:1 (avg mass : 1422.3129 )
- Hex:4 HexNAc:3 dHex:2 (avg mass : 1568.4559 )
- Hex:4 HexNAc:3 dHex:3 (avg mass : 1714.5989 )
- Hex:4 HexNAc:6 dHex:4 (avg mass : 2470.3269 )
- Hex:4 HexNAc:7 dHex:2 (avg mass : 2381.2359 )
- Hex:4 HexNAc:7 dHex:3 (avg mass : 2527.3789 )
- Hex:5 HexNAc:2 (avg mass : 1235.1173 )
- Hex:5 HexNAc:2 dHex:1 (avg mass : 1381.2603 )
- Hex:5 HexNAc:2 dHex:2 (avg mass : 1527.4033 )
- Hex:5 HexNAc:3 (avg mass : 1438.3123 )
- Hex:5 HexNAc:3 dHex:1 (avg mass : 1584.4553 )
- Hex:5 HexNAc:3 dHex:2 (avg mass : 1730.5983 )
- Hex:5 HexNAc:4 dHex:2 (avg mass : 1933.7933 )
- Hex:5 HexNAc:4 dHex:3 (avg mass : 2079.9363 )
- Hex:5 HexNAc:4 dHex:4 (avg mass : 2226.0793 )
- Hex:5 HexNAc:4 dHex:5 (avg mass : 2372.2223 )
- Hex:6 HexNAc:2 (avg mass : 1397.2597 )
- Hex:6 HexNAc:3 (avg mass : 1600.4547 )
- Hex:6 HexNAc:4 dHex:1 (avg mass : 1949.7927 )
- Hex:6 HexNAc:4 dHex:3 (avg mass : 2242.0787 )
- Hex:6 HexNAc:8 (avg mass : 2616.4297 )
- Hex:7 HexNAc:2 (avg mass : 1559.4021 )
- Hex:7 HexNAc:3 (avg mass : 1762.5971 )
- Hex:7 HexNAc:4 (avg mass : 1965.7921 )
- Hex:7 HexNAc:4 dHex:3 (avg mass : 2404.2211 )
- Hex:7 HexNAc:5 dHex:2 (avg mass : 2461.2731 )
- Hex:7 HexNAc:6 dHex:4 NeuAc:2 (avg mass : 3539.2699 )
- Hex:7 HexNAc:7 dHex:1 (avg mass : 2721.5201 )
- Hex:7 HexNAc:7 dHex:3 (avg mass : 3013.8061 )
- Hex:7 HexNAc:8 (avg mass : 2778.5721 )
- Hex:8 HexNAc:2 (avg mass : 1721.5445 )
- Hex:8 HexNAc:6 (avg mass : 2534.3245 )
- Hex:9 HexNAc:2 (avg mass : 1883.6869 )
- Hex:9 HexNAc:4 dHex:1 (avg mass : 2436.2199 )
- Hex:10 HexNAc:2 (avg mass : 2045.8293 )
- Hex:11 HexNAc:2 (avg mass : 2207.9717 )
Composition
- COVID-19 (DOID:0080600)
Disease
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
Reference
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
Reported glycosite
- SNVTWF (6aa)
- FSNVTWF (7aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- FSNVTW (6aa)
- FHAIHVSGTNGTK (13aa)
- HAIHVSGTNGTK (12aa)
- FHAIHVSGTNGTKR (14aa)
- HAIHVSGTNGTKR (13aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- FQFCNDPFLGVYYHKNNKSWMESE (24aa)
- FQFCNDPFLGVYYHKNNK (18aa)
- FQFCNDPFLGVYYHKNNKSWMESEF (25aa)
- VCEFQFCNDPFLGVYYHKNNKSWMESEFR (29aa)
- FQFCNDPFLGVYYHKNNKSWME (22aa)
- VYSSANNCTFEY (12aa)
- SSANNCTF (8aa)
- SSANNCTFEY (10aa)
- VYSSANNCTFEYVSQPFLMDLEGK (24aa)
- SEFRVYSSANNCTFEYVSQPFLMDLE (26aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- VYSSANNCTFEYVSQPFLMDLEGKQGNFKNLR (32aa)
- VYSSANNCTF (10aa)
- VDLPIGINITR (11aa)
- PLVDLPIGINITR (13aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- NGTITDAVDCALDPLSETK (19aa)
- NGTITDAVDCALDPLSETKCTLK (23aa)
- TFLLKYNENGTITDAVDCALDPLSE (25aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPF (10aa)
- FPNITNL (7aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- KGIYQTSNFRVQPTESIVRFPNITNLCPFGE (31aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- SIVRFPNITNLCPFGE (16aa)
- FPNITNLCPFGE (12aa)
- GEVFNATRF (9aa)
- VFNATR (6aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- GGVSVITPGTNTSNQVAVLY (20aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- DPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (57aa)
- GGVSVITPGTNTSNQVAVL (19aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- YQDVNCTEVPVAIHADQL (18aa)
- QDVNCTEVPVAIHADQL (17aa)
- AGCLIGAEHVNNSY (14aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYECDIPIGAGICASYQTQTNSPR (28aa)
- HVNNSYE (7aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- SNNSIAIPTNF (11aa)
- SNNSIAIPTNF (11aa)
- DFGGFNF (7aa)
- NFSQILPDPSK (11aa)
- DFGGFNFSQILPDPSK (16aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- VPAQEKNF (8aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- KNFTTAPAICHDGK (14aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- CVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPRE (61aa)
- AHFPREGVFVSNGTHWFVTQR (21aa)
- AHFPREGVFVSNGTHWFVTQR (21aa)
- KNFTTAPAICHDGKAHFPRE (20aa)
- NFTTAPAICHDGKAHFPR (18aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- HVTYVPAQEKNF (12aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- GVFVSNGTHWFVTQR (15aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- YFKNHTSPDVDLGDISGINASVVNIQKE (28aa)
- YFKNHTSPDVDLGDISGINASVVNIQKE (28aa)
- KNHTSPDVDLGDISGINASVVNIQK (25aa)
- NHTSPDVDLGDISGINASVVNIQKEIDR (28aa)
- EIDRLNEVAKNLNESLIDLQELGK (24aa)
- LNEVAKNLNESLIDLQELGK (20aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- IDRLNEVAKNLNE (13aa)
- LNEVAKNLNESLIDLQELGKYEQYIK (26aa)
- NLNESLIDLQELGKYEQYIK (20aa)
- NLNESLIDLQE (11aa)
- VAKNLNESLIDLQE (14aa)
Mass spectrometry observed peptide
-
- HexNAc:1 / N-Linked (avg mass : 221.2103)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- TQSLLIVNNATNVVIK (16aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPFGE (12aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSK (16aa)
- KNFTTAPAICHDGK (14aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- NFTTAPAICHDGK (13aa)
- GVFVSNGTHWFVTQR (15aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- VAKNLNESLIDLQE (14aa)
-
- HexNAc:1 dHex:1 / N-Linked (avg mass : 367.3533)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- TQSLLIVNNATNVVIK (16aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPFGE (12aa)
- AGCLIGAEHVNNSYE (15aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- KNFTTAPAICHDGK (14aa)
- NFTTAPAICHDGK (13aa)
- GVFVSNGTHWFVTQR (15aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- VAKNLNESLIDLQE (14aa)
-
- HexNAc:2 / N-Linked (avg mass : 424.4053)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- TQSLLIVNNATNVVIK (16aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- NFTTAPAICHDGK (13aa)
- GVFVSNGTHWFVTQR (15aa)
- VAKNLNESLIDLQE (14aa)
-
- HexNAc:1 dHex:2 / N-Linked (avg mass : 513.4963)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- AGCLIGAEHVNNSYE (15aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- KNFTTAPAICHDGK (14aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNESLIDLQE (14aa)
-
- HexNAc:2 dHex:1 / N-Linked (avg mass : 570.5483)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- AGCLIGAEHVNNSYE (15aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:1 HexNAc:2 / N-Linked (avg mass : 586.5477)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SEFRVYSSANNCTFE (15aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- NFTTAPAICHDGK (13aa)
- EGVFVSNGTHW (11aa)
- GVFVSNGTHWFVTQR (15aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- VAKNLNESLIDLQE (14aa)
-
- HexNAc:2 dHex:2 / N-Linked (avg mass : 716.6913)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SEFRVYSSANNCTFE (15aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- AGCLIGAEHVNNSYE (15aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:1 HexNAc:2 dHex:1 / N-Linked (avg mass : 732.6907)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- TQSLLIVNNATNVVIK (16aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GVFVSNGTHWFVTQR (15aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:2 HexNAc:2 / N-Linked (avg mass : 748.6901)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- HAIHVSGTNGTK (12aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPFGE (12aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSK (16aa)
- NFSQILPDPSK (11aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- VPAQEKNF (8aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- NFTTAPAICHDGK (13aa)
- GVFVSNGTHWFVTQR (15aa)
- VSNGTHWF (8aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:1 HexNAc:2 dHex:2 / N-Linked (avg mass : 878.8337)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQKE (28aa)
- YFKNHTSPDVDLGDISGINASVVNIQKE (28aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:2 HexNAc:2 dHex:1 / N-Linked (avg mass : 894.8331)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SNVTWF (6aa)
- FHAIHVSGTNGTK (13aa)
- HAIHVSGTNGTK (12aa)
- FHAIHVSGTNGTKR (14aa)
- HAIHVSGTNGTKR (13aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- FQFCNDPFLGVYYHKNNK (18aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- SSANNCTF (8aa)
- NGTITDAVDCALDPLSE (17aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPF (10aa)
- SIVRFPNITNLCPFGE (16aa)
- FPNITNLCPFGE (12aa)
- FPNITNL (7aa)
- VFNATR (6aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- NFSQILPDPSK (11aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSK (16aa)
- KNFTTAPAICHDGK (14aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- VPAQEKNF (8aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- HVTYVPAQEKNF (12aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- VSNGTHW (7aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:3 HexNAc:2 / N-Linked (avg mass : 910.8325)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- FSNVTW (6aa)
- SNVTWF (6aa)
- HAIHVSGTNGTK (12aa)
- FHAIHVSGTNGTKR (14aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- SEFRVYSSANNCTFEYVSQPFLMDLE (26aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- SSANNCTF (8aa)
- VYSSANNCTF (10aa)
- NGTITDAVDCALDPLSE (17aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPF (10aa)
- FPNITNLCPFGE (12aa)
- FPNITNL (7aa)
- KGIYQTSNFRVQPTESIVRFPNITNLCPFGE (31aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- GGVSVITPGTNTSNQVAVL (19aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- YQDVNCTEVPVAIHADQL (18aa)
- QDVNCTEVPVAIHADQL (17aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNF (7aa)
- NFSQILPDPSK (11aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSK (16aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- KNFTTAPAICHDGK (14aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- CVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPRE (61aa)
- VPAQEKNF (8aa)
- AHFPREGVFVSNGTHWFVTQR (21aa)
- AHFPREGVFVSNGTHWFVTQR (21aa)
- NFTTAPAICHDGKAHFPR (18aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- HVTYVPAQEKNF (12aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- IDRLNEVAKNLNE (13aa)
- NLNESLIDLQE (11aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:2 HexNAc:3 / N-Linked (avg mass : 951.8851)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- IVNNATNVVIK (11aa)
-
- Hex:2 HexNAc:2 dHex:2 / N-Linked (avg mass : 1040.9761)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- TQSLLIVNNATNVVIK (16aa)
- FQFCNDPFLGVYYHKNNK (18aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- FPNITNLCPFGE (12aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- SIVRFPNITNLCPFGE (16aa)
- VFNATR (6aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSK (16aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- KNFTTAPAICHDGKAHFPRE (20aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GVFVSNGTHWFVTQR (15aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- NLNESLIDLQELGKYEQYIK (20aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:3 HexNAc:2 dHex:1 / N-Linked (avg mass : 1056.9755)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- FSNVTW (6aa)
- SNVTWF (6aa)
- FHAIHVSGTNGTK (13aa)
- HAIHVSGTNGTK (12aa)
- FHAIHVSGTNGTKR (14aa)
- HAIHVSGTNGTKR (13aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- FQFCNDPFLGVYYHKNNKSWMESE (24aa)
- FQFCNDPFLGVYYHKNNKSWME (22aa)
- VYSSANNCTFEY (12aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- SSANNCTF (8aa)
- VYSSANNCTF (10aa)
- SSANNCTFEY (10aa)
- VDLPIGINITR (11aa)
- PLVDLPIGINITR (13aa)
- NGTITDAVDCALDPLSE (17aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPF (10aa)
- SIVRFPNITNLCPFGE (16aa)
- FPNITNLCPFGE (12aa)
- FPNITNL (7aa)
- VFNATR (6aa)
- GEVFNATR (8aa)
- GEVFNATRF (9aa)
- CPFGEVFNATR (11aa)
- GGVSVITPGTNTSNQVAVLY (20aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- YQDVNCTEVPVAIHADQL (18aa)
- QDVNCTEVPVAIHADQL (17aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYECDIPIGAGICASYQTQTNSPR (28aa)
- AGCLIGAEHVNNSY (14aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNF (7aa)
- NFSQILPDPSK (11aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSK (16aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- KNFTTAPAICHDGK (14aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- VPAQEKNF (8aa)
- KNFTTAPAICHDGKAHFPRE (20aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- HVTYVPAQEKNF (12aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- IDRLNEVAKNLNE (13aa)
- NLNESLIDLQELGKYEQYIK (20aa)
- NLNESLIDLQE (11aa)
- VAKNLNESLIDLQE (14aa)
- EIDRLNEVAKNLNESLIDLQELGK (24aa)
-
- Hex:4 HexNAc:2 / N-Linked (avg mass : 1072.9749)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- VYSSANNCTF (10aa)
- SSANNCTFEY (10aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- FPNITNLCPF (10aa)
- FPNITNL (7aa)
- VFNATR (6aa)
- GEVFNATR (8aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- AGCLIGAEHVNNSYE (15aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- NFSQILPDPSK (11aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- VPAQEKNF (8aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- NFTTAPAICHDGK (13aa)
- GVFVSNGTHWFVTQR (15aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- EGVFVSNGTHW (11aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- VAKNLNE (7aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:2 HexNAc:3 dHex:1 / N-Linked (avg mass : 1098.0281)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- HAIHVSGTNGTK (12aa)
-
- Hex:3 HexNAc:3 / N-Linked (avg mass : 1114.0275)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- FSNVTW (6aa)
- SNVTWF (6aa)
- FHAIHVSGTNGTK (13aa)
- HAIHVSGTNGTKR (13aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- FQFCNDPFLGVYYHKNNKSWMESE (24aa)
- FQFCNDPFLGVYYHKNNKSWME (22aa)
- VYSSANNCTFEYVSQPFLMDLEGK (24aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- SSANNCTF (8aa)
- VYSSANNCTF (10aa)
- SSANNCTFEY (10aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPF (10aa)
- FPNITNLCPFGE (12aa)
- VFNATR (6aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNF (7aa)
- NFSQILPDPSK (11aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- KNFTTAPAICHDGK (14aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- CVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPRE (61aa)
- VPAQEKNF (8aa)
- KNFTTAPAICHDGKAHFPRE (20aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- HVTYVPAQEKNF (12aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:3 HexNAc:2 dHex:2 / N-Linked (avg mass : 1203.1185)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- TQSLLIVNNATNVVIK (16aa)
- FQFCNDPFLGVYYHKNNKSWMESE (24aa)
- FQFCNDPFLGVYYHKNNK (18aa)
- FQFCNDPFLGVYYHKNNKSWMESEF (25aa)
- FQFCNDPFLGVYYHKNNKSWME (22aa)
- VYSSANNCTFEYVSQPFLMDLEGK (24aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- PLVDLPIGINITR (13aa)
- NGTITDAVDCALDPLSETK (19aa)
- NGTITDAVDCALDPLSETKCTLK (23aa)
- NGTITDAVDCALDPLSE (17aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- SIVRFPNITNLCPFGE (16aa)
- FPNITNLCPFGE (12aa)
- KGIYQTSNFRVQPTESIVRFPNITNLCPFGE (31aa)
- VFNATR (6aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSK (16aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- KNFTTAPAICHDGK (14aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- CVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPRE (61aa)
- KNFTTAPAICHDGKAHFPRE (20aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- GVFVSNGTHWFVTQR (15aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQKEIDR (28aa)
- LNEVAKNLNESLIDLQELGK (20aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- IDRLNEVAKNLNE (13aa)
- LNEVAKNLNESLIDLQELGKYEQYIK (26aa)
- NLNESLIDLQELGKYEQYIK (20aa)
- NLNESLIDLQE (11aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:4 HexNAc:2 dHex:1 / N-Linked (avg mass : 1219.1179)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- VYSSANNCTFEY (12aa)
- SEFRVYSSANNCTFE (15aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- FPNITNLCPFGE (12aa)
- FPNITNL (7aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- VPAQEKNF (8aa)
- HVTYVPAQEKNF (12aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHW (11aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- VAKNLNE (7aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:5 HexNAc:2 / N-Linked (avg mass : 1235.1173)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- FSNVTW (6aa)
- SNVTWF (6aa)
- FHAIHVSGTNGTK (13aa)
- HAIHVSGTNGTK (12aa)
- HAIHVSGTNGTKR (13aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- SSANNCTF (8aa)
- SSANNCTFEY (10aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPFGE (12aa)
- FPNITNL (7aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- QDVNCTEVPVAIHADQL (17aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- NFSQILPDPSK (11aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSK (16aa)
- KNFTTAPAICHDGK (14aa)
- VPAQEKNF (8aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- HVTYVPAQEKNF (12aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:2 HexNAc:3 dHex:2 / N-Linked (avg mass : 1244.1711)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- VPAQEKNFTTAPAICHDGK (19aa)
-
- Hex:3 HexNAc:3 dHex:1 / N-Linked (avg mass : 1260.1705)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- FHAIHVSGTNGTK (13aa)
- HAIHVSGTNGTK (12aa)
- FHAIHVSGTNGTKR (14aa)
- HAIHVSGTNGTKR (13aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- VCEFQFCNDPFLGVYYHKNNKSWMESEFR (29aa)
- FQFCNDPFLGVYYHKNNKSWME (22aa)
- VYSSANNCTFEYVSQPFLMDLEGK (24aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- VYSSANNCTFEYVSQPFLMDLEGKQGNFKNLR (32aa)
- SSANNCTF (8aa)
- SSANNCTFEY (10aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPF (10aa)
- VFNATR (6aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- QDVNCTEVPVAIHADQL (17aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- KNFTTAPAICHDGK (14aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- CVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPRE (61aa)
- VPAQEKNF (8aa)
- KNFTTAPAICHDGKAHFPRE (20aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- HVTYVPAQEKNF (12aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- NLNESLIDLQELGKYEQYIK (20aa)
- VAKNLNESLIDLQE (14aa)
- EIDRLNEVAKNLNESLIDLQELGK (24aa)
-
- Hex:4 HexNAc:3 / N-Linked (avg mass : 1276.1699)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- FSNVTW (6aa)
- HAIHVSGTNGTK (12aa)
- FHAIHVSGTNGTKR (14aa)
- FHAIHVSGTNGTK (13aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- SSANNCTF (8aa)
- SSANNCTFEY (10aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- VFNATR (6aa)
- GEVFNATR (8aa)
- QDVNCTEVPVAIHADQL (17aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- VPAQEKNF (8aa)
- HVTYVPAQEKNF (12aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- NFTTAPAICHDGK (13aa)
- GVFVSNGTHWFVTQR (15aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:3 HexNAc:4 / N-Linked (avg mass : 1317.2225)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- EGVFVSNGTHW (11aa)
- GVFVSNGTHWFVTQR (15aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- VAKNLNE (7aa)
-
- Hex:2 HexNAc:5 / N-Linked (avg mass : 1358.2751)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- EGVFVSNGTHW (11aa)
-
- Hex:4 HexNAc:2 dHex:2 / N-Linked (avg mass : 1365.2609)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- TQSLLIVNNATNVVIK (16aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPFGE (12aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYE (7aa)
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide